UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.